Subcutaneous sites tolerate more frequent reuse
Research published in Cell Reports Medicine in 2026 concluded directly: weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function
CVD: Cardiovascular Disease Although several in-line GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs have approved indications beyond T2D and overweight/ obesity, US Pharmacopeia Drug Classification (USP DC) 2025 limits classification to categories/classes according to their primary diagnosis (e.g., antidiabetic
Cardiovascular health People with existing cardiovascular conditions should approach any new compound cautiously
Insurance companies like Aetna, Cigna, United Healthcare, BlueCross BlueShield, Molina, and Oscar Insurance cover Wegovy, but most of them require prior authorization (PA) before they pay for it
A study examining weight outcomes in patients using GLP-1 agonists found that those concurrently taking any antidepressant, including bupropion, lost slightly less weight on average compared to those not taking antidepressants
